Selective vertical transmission of HIV-1 antiretroviral resistance mutations

AIDS

Volumn 12, Issue 17, 1998, Pages 2281-2288

  Colgrove, Robert C ^a,d   Pitt, Jane ^b   Chung, Pei Hua ^a   Welles, Seth L ^c   Japour, Anthony J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Columbia Univ Coll Phys Surgs ^*  (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Drug resistance; Vertical transmission; Zidovudine

Indexed keywords

ANTIVIRUS AGENT; RNA DIRECTED DNA POLYMERASE; VIRUS ENZYME; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; DRUG RESISTANCE; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RNA SEQUENCE; VERTICAL TRANSMISSION;

EID: 0032481063     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199817000-00009     Document Type: Article

References (29)

1. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
2. Coffin JM: HIV viral dynamics. AIDS 1996, 10 (suppl 3):S75-S84.
3. Ho DD: HIV-1 dynamics in vivo. J Biol Regul Homeost Agents 1995, 9:76-77.
4. Mansky LM, Temin H M: Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995, 69:5087-5094.
5. Leal M, Rey C, Torres Y, et al.: Rate of development of mutation at codon 215 of HIV-1 reverse transcriptase and its predictive factors at the time of initiation of zidovudine therapy. Eur J Clin Invest 1996, 26:476-480.
6. Mansky LM: Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line. AIDS Res Hum Retroviruses 1996, 12:307-314.
7. Katzenstein DA, Holodniy M: HIV viral load quantification, HIV resistance, and antiretroviral therapy. AIDS Clin Rev 1995, 96:277-303.
8. Mayers DL, Japour AJ, Arduino JM, et al.: Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group. Antimicrob Agents Chemother 1994, 38:307-314.
9. Wolf E, Virgin G, Dietrich U, et al.: The impact of genotype drug resistance on viral burden. XI International Conference on AIDS. Vancouver, July 1996 [abstract ThB4343].
10. Nowak MA, Bonhoeffer S, Shaw GM, May RM: Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J Theor Biol 1997, 184:203-217.
11. Arts EJ, Wainberg MA: Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother 1996, 40:527-540.
12. Erickson JW, Burt SK: Structural mechanisms of HIV drug resistance. Annu Rev Pharmacol Toxicol 1996, 36:545-571.
13. Lipsky JJ: Antiretroviral drugs for AIDS. Lancet 1996, 348:800-803.
14. Richman DD: HIV drug resistance. Annu Rev Pharmacol Toxicol 1993, 33:149-164.
15. Japonr AJ, Welles S, D'Aquila RT, et al.: Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis 1995, 171:1172-1179.
16. D'Aquila RT, Johnson VA, Welles SL, et al.: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995, 122:401-408.
17. Smith M, Salomon H, Wainberg MA: Development and significance of nucleoside drug resistance in infection caused by the human immunodeficiency virus type 1. Clin Invest Med 1994, 17:226-243.
18. Kuritzkes DR: Clinical significance of drug resistance in HIV-1 infection. AIDS 1996, 10 (suppl 5):S27-S31.
19. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331:1173-1180.
20. Sperling RS, Shapiro DE, Coombs RW, et al.: Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996, 335:1621-1629.
21. D'Aquila RT: HIV-1 drug resistance. Molecular pathogenesis and laboratory monitoring. Clin Lab Med 1994, 14:393-422.
22. Colgrove R, Japour A: Mathematical modeling of within-patient evolution of HIV-1 antiretroviral resistance as a function of HIV reverse transcriptase fidelity and total-body HIV virion burden predicts sharp non-linear superiority of three-drug over two-drug therapeutic regimens. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 406].
23. Hollinger F, Bremer J, Myers L, Gold J, McQuay L: Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J Clin Microbiol 1992, 30:1787-1794.
24. Brown AJ, Richman DD: HIV-1: gambling on the evolution of drug resistance? Nat Med 1997, 3:268-271.
25. Sharma PL, Crumpacker CS: Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J Virol 1997, 71:8846-8851.
26. Wolinsky SM, Wike CM, Korber BT, et al.: Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992, 255:1134-1137.
27. Sabino E, Pan LZ, Cheng-Mayer C, Mayer A: Comparison of in vivo plasma and peripheral blood mononuclear cell HIV-1 quasispecies to short-term tissue culture isolates: an analysis of tat and C2-V3 env regions. AIDS 1994, 8:901-909.
28. Hahn BH, Shaw GM: Genetic variation among isolates of HIV-1 and HIV-2. In HIV Detection by Genetic Engineering Methods. Edited by Luciw PA, Steimer KS. New York: Marcel Dekker; 1989:257-273.
29. Hooker D, Tachedjian G, Solomon A, et al.: High level resistance to AZT in association with a leucine to tryptophan change at amino acid 210 of HIV-1 reverse transcriptase. Second National Conference on Human Retroviruses and Related Infections. Washington, DC, January 1995 [abstract 139].